Promising immunotherapy currently under evaluation for advance gynecologic cancers #SGOmtg

Promising immunotherapy currently under evaluation for advance gynecologic cancers #SGOmtg

sgo2016

3 years
471 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Michael J. Birrer, MD of Massachusetts General Hospital discusses promising immunotherapy currently under evaluation for advance gynecologic cancers at SGO 2016.

Transcription:

Well I think the checkpoint hitters are the hot ones partly because they they've got eggs terrific track record and other tumors into easy to give their antibodies but it's been a long track record of immunotherapy. In gynecologic cancers the the. Pennsylvania group where George Lucas was now Georges and in Switzerland was doing adopted TCL approaches and there were some promising results with that the problem is it's it's. Resource intensive credibly expensive and toxic. But that's still being at still being approach Carty. Which has had a very impressive splash with childhood. Cancers I know for a fact there's a trial in ovarian cancer targeting I believe mesothelioma has the target. Cleanly done say up in Roswell has multiple immunotherapy trials. Some of which are vaccine based. I think one of the clever approaches which we are trying to design now in other centers are is. To take over in cancer the time of of the bulking so there's lots of tumor and do whole Exum sequencing.
Up Next Autoplay
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 2 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 2 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 2 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 2 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
0 Views
Cancer-News 2 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 2 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 3 days
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
5 Views
Cancer-News 4 days
Molecular AI Product: What's Next For Research?
Molecular AI Product: What's Next For Research?
Category: News
11 Views
Cancer-News 1 week
Molecular AI Product: Can It Be Used Now or Later?
Molecular AI Product: Can It Be Used Now or Later?
Category: News
9 Views
Cancer-News 1 week